◼ Archived
Business
Roche drops muscle-sparing obesity antibody after flunked interim analysis
0sources
0articles
0velocity
47d agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (0)
Related trends
▲ Peaking
Business
A Larger-Than-Normal Fed Rate Hike in December Now Looks More Likely. Here's Why.
▲ Peaking
Business
The hottest job in AI right now may be counterintelligence as companies hire to protect secrets
▲ Peaking
Business
How Nvidia's scandal knocked thousands off your 401(k)
▲ Peaking
Business
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
▲ Peaking
Business
Outlook Went Down? Microsoft May Owe You Money
▲ Peaking
Business
The Stock Market Is Doing Something for Only the 6th Time in 156 Years, and History Says It's Clear What Comes Next for Stocks
Unprecedented stock market patterns spark intense debate across financial media as analysts weigh historic parallels against record highs.